Delivery Order SPE2DB22D1106-SPE2DB25FFEP2
- Not listed
- The Defense Logistics Agency awarded a $1,790.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). The contract, which is a non-set-aside competitive award with an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. This delivery order will be fulfilled from the vendor's facility in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,646.08 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml), a local anesthetic pharmaceutical product. The contract, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a firm fixed-price delivery order with no set-aside designation. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,342.70 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL vials). This firm fixed price contract, issued on August 15, 2025, represents a competitively awarded procurement with no set-aside designation and an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Ropivacaine 0.2% in 400 mg/200 ml doses, with a contract ceiling value of $5,062.74 and an ultimate completion date of August 25, 2025. This is a firm fixed-price delivery order executed under a competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $3,235.22 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 mL) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply services to the federal government and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a wholly owned subsidiary of Amerisourcebergen Corporation, to provide 4556997205 - Ropivacaine 0.2% 200 mg/100 ml 100 ml pharmaceuticals. The contract award, valued at $2,695.54, has an ultimate completion date of April 27, 2022. This delivery order is issued under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, valued up to $999,999,999.00 with a...
- This contract award is for the delivery of 400 mg/200 mL vials of ropivacaine 0.2% solution, a local anesthetic medication, to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order, valued at $3,873.51, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has an ultimate completion date of October 27, 2023 and is not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
- This contract award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug Corp with the Defense Logistics Agency (DLA) Troop Support Medical. The IDC, valued at $999,999,999, provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The specific delivery order is for 400 mg/200 mL of the drug Ropivacaine 0.2%, totaling $3,736.40. The contract does not have a set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,781.85, is a Delivery Order for the supply of Ropivacaine 0.2% 400 mg/200 ml medical products. The award is not associated with any set-aside program and has an ultimate completion date of May 24, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract is for the supply of Ropivacaine 0.2% 200 mg/100 mL, a local anesthetic medication, with a ceiling value of $1,029.75 and an ultimate completion date of August 29, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFEP2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,410.92 to AmerisourceBergen Drug Corp for the supply of Ropivacaine 0.2% (400 mg/200 ml, 200 ml units) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this order under its existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026. The Ropivacaine supply order supports the Defense Health Agency and broader military healthcare operations by providing a local anesthetic pharmaceutical commonly used in medical procedures. AmerisourceBergen's portfolio of federal awards demonstrates consistent capability in competitively delivering diverse pharmaceutical products, from specialty medications to generic drugs, across multiple therapeutic domains. The company's significant IDC vehicle with DLA enables flexible fulfillment of pharmaceutical requirements for military healthcare systems, positioning it as a key supplier within the Defense Health Agency's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/21/25 |